Advisory Committee (CFSAC) meeting are now available via YouTube at the fol=
lowing link:=0A=0Ahttp://www.youtube.com/playlist?list=3DPL600CB038194B4593=
=0A=0A=0APresentations by invited speakers in PDF format (as well as the vi=
deos) may be accessed here:=0A=0Ahttp://www.hhs.gov/advcomcfs/meetings/pres=
entations/11082011.html=0A=0A=0ADon't forget that anyone who wants to send =
the following message to the Federal officials present at the meeting,=0A=
=0A"Double the current NIH funding for extramural research. Priority should=
be given to research on biomarkers and potential pathogens as well as clin=
ical trials.=A0=A0Take down information on the CDC's CFS website stating te=
sting for pathogens and biomarkers is "experimental and theoretical" and th=
at GET and CBT are appropriate treatments."=0A=0A=0Amay do so simply by sig=
ning the below petition which will result in emails being sent to the relev=
ant parties. =A0This is the message that was presented by most testifying a=
s well as the public representatives on the CFSAC. (Your email address is n=
ot shared if that is a concern.)=0A=0Ahttp://www.change.org/petitions/apolo=
gize-for-not-responding-appropriately-to-the-mecfs-epidemic=0A=0A=0A--Liz W=
illow
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
Too much mail? Try a digest version. See http://www.co-cure.org/digest.htm
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
